USA flag logo/image

An Official Website of the United States Government

THE USE OF IN VITRO PRODUCED MONOCLONAL ANTIBODIES FOR THE TREATMENT OF…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
5325
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
5325
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Verax Corp
Etna Rd Hc 61 Box 6 Lebanon, NH 03766
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: THE USE OF IN VITRO PRODUCED MONOCLONAL ANTIBODIES FOR THE TREATMENT OF IMMUNOLOGIC, INFECTIOUS, AND NEOPLASTIC DISEASES IN HUMANS IS PROJECTED TO INCREASE SHARPLY IN THE UPCOMING YEARS.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE USE OF IN VITRO PRODUCED MONOCLONAL ANTIBODIES FOR THE TREATMENT OF IMMUNOLOGIC, INFECTIOUS, AND NEOPLASTIC DISEASES IN HUMANS IS PROJECTED TO INCREASE SHARPLY IN THE UPCOMING YEARS. VERAX CORPORATION HAS DEVELOPED A NOVEL SYSTEM FOR THE MASS CULTURE OF HYBRIDOMA CELLS AS WELL AS SEVERAL PROPRIETARY SERUM-FREE MEDIA. IN A LARGE-SCALE CONTINUOUS CULTURE SYSTEM, ALBUMIN-CONTAINING MEDIUM IS MOREEFFECTIVE IN SUPPORTING HYBRIDOMA CULTURES THAN IS MEDIUM THAT LACKS ALBUMIN, BUT IS SUPPLEMENTED WITH OTHER LIPID- CARRYING COMPONENTS. THIS PROJECT WILL EXTEND THE DEVELOP- MENT OF SERUM-FREE MEDIUM FOR THE CULTURE OF HYBRIDOMA CELLSBY USING LIPID-CARRYING FRAGMENTS OF ALBUMIN TO REPLACE THE USE OF THE WHOLE MOLECULE. PURIFIED BOVINE SERUM ALBUMIN WILL BE CLEAVED BY CHEMICAL AND ENZYMATIC MEANS AND VARIOUS PEPTIDES SEPARATED BY HIGH PERFORMANCE ION EXCHANGE AND GEL FILTRATION CHROMATOGRAPHY. THE FATTY ACID BINDING CAPABILI-TIES, AS WELL AS THE POSSIBLE DETOXIFICATION POTENTIAL OF THESE FRAGMENTS, WILL THEN BE STUDIED IN VITRO. THE USE OF A SERUM-FREE MEDIUM FOR TISSUE CULTURE THAT CONTAINS SMALL POLYPEPTIDE(S) COULD PROVE TO BE EXTREMELY ECONOMICAL BY CUTTING COSTS IN THE PREPARATION OF MEDIUM AND IN THE PURIFICATION OF THE ANTIBODY. WHILE THIS STUDY WILL UTILIZEHYBRIDOMA CELLS, THE USES OF THIS MEDIUM MAY NOT BE LIMITED TO THIS CELL TYPE.

Principal Investigator:

Amar s tung
PRINCIPAL INVESTIGATOR
6034484445

Business Contact:

Small Business Information at Submission:

Verax Corpon
Etna Road, Hc 61, Box 6 Lebanon, NH 03766

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No